loading...| Preferred Name |
Ipilimumab |
|
| Synonyms |
Ipilimumab Biosimilar CS1002 Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody BMS-734016 IPILIMUMAB Ipilimumab MDX-010 MDX-CTLA4 Yervoy ipilimumab |
|
| Definitions |
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2654 |
|
| Accepted_Therapeutic_Use_For |
Unresectable or Metastatic Melanoma |
|
| ALT_DEFINITION |
A monoclonal antibody being studied in the treatment of certain types of cancer. Ipilimumab is made in the laboratory and binds to the molecule CTLA-4 on T cells (a type of white blood cell). Ipilimumab may block CTLA-4 and help the immune system kill cancer cells. |
|
| CAS_Registry |
477202-00-9 |
|
| code |
C2654 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. |
|
| Display_Name |
Ipilimumab |
|
| FDA_UNII_Code |
6T8C155666 |
|
| FULL_SYN |
Ipilimumab Biosimilar CS1002 Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody BMS-734016 IPILIMUMAB Ipilimumab MDX-010 MDX-CTLA4 Yervoy ipilimumab |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Ipilimumab |
|
| Legacy Concept Name |
Anti-Cytotoxic_T-Lymphocyte-Associated_Antigen-4_Monoclonal_Antibody |
|
| Maps_To |
Ipilimumab |
|
| NCI_Drug_Dictionary_ID |
38447 |
|
| NSC Number |
720801 732442 |
|
| PDQ_Closed_Trial_Search_ID |
38447 |
|
| PDQ_Open_Trial_Search_ID |
38447 |
|
| Preferred_Name |
Ipilimumab |
|
| prefixIRI |
Thesaurus:C2654 |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C1367202 |
|
| subClassOf |